Skip to main content

Advertisement

SpringerLink
Log in

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort

  • Brief Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The use of clinicopathologic features in decision-making in early stage estrogen receptor (ER)-positive breast cancer (BC) may lead to over or under treatment. We investigated the effect of the Oncotype Dx® (ODX) on chemotherapy (CTX) utilization in two cancer centers. 276 cases of node-negative ER-positive BC had ODX between 2005 and 2009. Age at diagnosis, tumor size, grade, and progesterone receptor (PR) status were abstracted from records and provided to two medical oncologists blinded to the ODX score. A recommendation for or against CTX was made based on clinicopathologic characteristics. Median age was 55 years. Mean tumor size was 1.6 cm. The median 10-year Adjuvant! Online (AO) mortality risk was 8. The median Nottingham Prognostic Index (NPI) was 3.3. The median ODX recurrence score was 17. Without knowledge of the ODX, oncologists were more likely to recommend CTX to younger women (P < 0.0001), women with negative PR status (P < 0.0001), higher NPI (P < 0.012), and tumors > 1 cm (P = 0.033). On average, CTX recommended patients had larger tumors (2.0 vs. 1.2 cm) and higher AO 10-year mortality (11.4 vs. 4.4%). ODX resulted in a change in management for 38% of women. Of 188 total patients who did not receive CTX, 71 had a recommendation favoring CTX by an oncologist blinded to the ODX score. In our multi-institutional cohort, the ODX score had a significant impact on the receipt of adjuvant CTX and altered management for 38% of women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130

    Article  PubMed  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717

    Article  Google Scholar 

  3. Network NCC: Breast Cancer. In: NCCN Clinical Practice Guidelines in Oncology. vol. 2010; 2010

  4. Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW (2009) The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99(6):319–323

    Article  PubMed  CAS  Google Scholar 

  5. Oratz R, Paul D, Cohn AL, Sedlacek SM (2007) Impact of a commercial reference laboratory test recurrence score on decision making in early stage breast cancer. J Oncol Pract 3(4):182–186

    Article  PubMed  Google Scholar 

  6. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI (2008) Does oncotype DX recurrence score affect the management of patients with early stage breast cancer? Am J Surg 196(4):527–529

    Article  PubMed  Google Scholar 

  7. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671–1676

    Article  PubMed  Google Scholar 

  8. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Perez EA et al. (2007) How well do standard prognostic criteria predict oncotype DX (ODX) scores? In: Proceedings of the American society of clinical oncology, vol 25. Journal of Clinical Oncology, Chicago

  9. Liang H, Brufsky AM, Lembersky BB, Rastogi P, Vogel VG (2007) A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. In: San Antonio Breast Cancer Symposium. American Association for Cancer Research, San Antonio

  10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826

    Article  PubMed  CAS  Google Scholar 

  11. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410

    Article  PubMed  CAS  Google Scholar 

  12. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980–991

    PubMed  CAS  Google Scholar 

  13. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56(4):489–492

    Article  PubMed  CAS  Google Scholar 

  14. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4):381–387

    Article  PubMed  Google Scholar 

  15. Lyman GH, Cosler LE, Kuderer NM, Hornberger J (2007) Impact of a 21-gene RT-PCR assay on treatment decisions in early stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109(6):1011–1018

    Article  PubMed  Google Scholar 

  16. Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early stage breast cancer. Am J Manag Care 11(5):313–324

    PubMed  Google Scholar 

  17. Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL (2005) The cost of adjuvant chemotherapy in patients with early stage breast carcinoma. Cancer 104(10):2054–2062

    Article  PubMed  Google Scholar 

  18. Chung M, Chang HR, Bland KI, Wanebo HJ (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77(1):97–103

    Article  PubMed  CAS  Google Scholar 

  19. Dirier A, Burhanedtin-Zincircioglu S, Karadayi B, Isikdogan A, Aksu R (2009) Characteristics and prognosis of breast cancer in younger women. J BUON 14(4):619–623

    PubMed  CAS  Google Scholar 

  20. Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST (2000) Stage 0 to stage III breast cancer in young women. J Am Coll Surg 190(5):523–529

    Article  PubMed  CAS  Google Scholar 

Download references

Financial disclosures

No financial disclosures or sources of support are reported for this study

Author information

Authors and Affiliations

  1. Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA

    Foluso O. Ademuyiwa, Austin Miller, Tracey O’Connor, Stephen B. Edge & Ellis Levine

  2. CRUK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

    Mangesh A. Thorat

  3. Indiana University School of Medicine, Indianapolis, IN, USA

    George W. Sledge & Sunil Badve

Authors
  1. Foluso O. Ademuyiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Austin Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tracey O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen B. Edge
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mangesh A. Thorat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. George W. Sledge
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ellis Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sunil Badve
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Foluso O. Ademuyiwa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ademuyiwa, F.O., Miller, A., O’Connor, T. et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 126, 797–802 (2011). https://doi.org/10.1007/s10549-010-1329-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1329-6

Keywords

Search

Navigation